Surrogate endpoints in clinical trials: definition and operational criteria.
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsStatistical issues in first-in-man studiesGlatiramer acetate for multiple sclerosisVaccines for preventing smallpoxMagnetic resonance imaging as a surrogate outcome for multiple sclerosis relapsesBarrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesisThe clinical use of structural MRI in Alzheimer diseaseBiomarkers and surrogate endpointsImputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpointA perfect correlate does not a surrogate makeCarotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitorsDietary phytochemicals and cancer chemoprevention: a review of the clinical evidencePredicting Clinical Outcomes Using Molecular BiomarkersFighting the Monster: Applying the Host Damage Framework to Human Central Nervous System InfectionsCharacterization of DNA Methylation in Circulating Tumor CellsConfirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceNeoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical TrialsTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsEarly events during neoplastic progression in Barrett's esophagusAssessing the Validity of Surrogate Outcomes for ESRD: A Meta-AnalysisLung cancer chemoprevention: current status and future prospectsEnd points for comparative effectiveness research in heart failureSurrogate endpoints in liver surgery related trials: a systematic review of the literatureThe perils of surrogate endpointsMammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapiesGroup B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countriesOptions for basing Dietary Reference Intakes (DRIs) on chronic disease endpoints: report from a joint US-/Canadian-sponsored working groupRecent developments in clinical trial designs for HIV vaccine researchGetting it right: being smarter about clinical trialsThe flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and childrenPrecursors in cancer epidemiology: aligning definition and functionPragmatic medicine in solid cancer: a translational alternative to precision medicineThe use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholdersComparing biomarkers as principal surrogate endpointsMissing data methods in longitudinal studies: a reviewCircumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malariaImaging biomarker roadmap for cancer studiesTranslating neoadjuvant therapy into survival benefits: one size does not fit all.Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trialsLong-term drug prevention trials.
P2860
Q21144611-1C0045AF-1DD6-45D9-BD2F-B6C8154731C3Q23018507-713FA560-B60D-46E8-9F91-785F3E2E3EDDQ24235498-EA5E3908-FE1D-48E1-9403-DC22EEF60AB2Q24244234-4B2A881D-BC70-4A4F-A9AE-65197159F71FQ24288978-3C1D4E83-9A2E-4CEB-9BC4-F2A2A534E037Q24602426-6506EF79-586E-4A08-9CDF-BEF11E6F22D4Q24609648-B6559BD6-FEC6-42C1-BEA0-EA52BC7C5FA7Q24678760-CF4629F8-9BEB-446C-83FD-7895DC02E1DBQ24793188-5808C410-68E8-4F02-8C6C-96EE316EEF73Q24803339-FF94276E-448B-4254-A378-2401D1F7E1FCQ24803555-8271E16D-AD57-47D8-A065-C687A42E353BQ26745552-29D39A44-7935-4A96-BAC3-7E387B4F6347Q26747424-DE47AAC9-4316-4CBD-B69E-912AC378DC6FQ26774211-6E7A8BEE-0DB8-4350-A93D-615EE534B06CQ26778427-7EE9C61C-155A-491D-A3FD-F2209711FE75Q26782138-AE659130-2DB3-41E1-9ED2-7BCA603E1005Q26796253-011281D4-D10F-4E1F-869E-BB2FBE6AD724Q26797292-2040BDC2-CAA5-4B13-9205-628F5DEF4E03Q26825349-A0F0D363-B76C-4775-920A-C6DD7B384314Q26863404-E9C87DD8-4896-47AC-B556-3B5C07BC8F7AQ26995495-950FDA5D-26BE-4598-BF9B-E13EA5045389Q27012843-14581993-7716-4301-A166-D4DE3DCF64FBQ27022533-81C27097-D32A-46AD-A8B0-627945568D1AQ27025740-341BE2F3-B435-410D-B86D-880DC4881FE4Q28074177-202CD324-1CA1-45AE-93AB-724D07AFAF65Q28075884-F2C6D001-9239-4ED4-94B4-EDBA4317281DQ28076931-15024670-9156-4238-AD2B-9DFA258E88F4Q28083514-5A13FC1F-7796-497A-95A1-D503030DF9AFQ28196471-21B4F1D5-A034-434C-AB34-A59FE4A09438Q28290097-17F230BD-6967-4752-8320-1AACB35374A7Q28387064-845AB1EE-D72C-4641-BFAA-C72736E635BEQ28391863-41B48BC5-3AD6-4089-A94E-17B9D937EB0AQ28543430-08A3C828-C66D-4473-8ED5-9E4CDF761103Q28740935-7F31148B-C956-444B-B726-1BBFF525477AQ28743676-49885EC8-943A-4B29-A9AB-C1926C2A13CAQ28744170-26F5E61A-2916-4CE8-B221-EBDCCFDB923EQ30242020-C1303BAA-4F46-44B0-926A-5D4EC1BEAECDQ30251738-4BED2A83-46D4-4703-84C2-53FF0BA3F490Q30359367-2A8311E0-6E01-4DF9-838C-59486091E8A0Q30368543-E79C8B60-634B-451B-BCB4-42F1804FB4C6
P2860
Surrogate endpoints in clinical trials: definition and operational criteria.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Surrogate endpoints in clinical trials: definition and operational criteria.
@en
type
label
Surrogate endpoints in clinical trials: definition and operational criteria.
@en
prefLabel
Surrogate endpoints in clinical trials: definition and operational criteria.
@en
P356
P1476
Surrogate endpoints in clinical trials: definition and operational criteria.
@en
P2093
Prentice RL
P304
P356
10.1002/SIM.4780080407
P407
P577
1989-04-01T00:00:00Z